Valuation: Revance Therapeutics, Inc.

Market Cap 319M 283M 264M 241M 455M 30.66B 459M 3.2B 1.24B 15.67B 1.2B 1.17B 50.3B P/E 2022
-3.77x
P/E 2023 -2.3x
Enterprise Value 543M 483M 451M 411M 775M 52.24B 782M 5.45B 2.11B 26.71B 2.04B 2B 85.71B EV / Sales 2022
12x
EV / Sales 2023 4.26x
Free-Float
91.93%
Yield 2022 *
-
Yield 2023 -
3 years 2.3
Extreme 2.3
10.92
5 years 2.3
Extreme 2.3
37.98
10 years 2.3
Extreme 2.3
37.98
Manager TitleAgeSince
Chief Executive Officer 55 01/10/2025
General Counsel - 04/02/2025
Director TitleAgeSince
Chairman - 01/10/2025
Date Insider Type Main position Quantity % Market Cap. Importance
04/02/25 Tender

Chairman

51,506 0.0493%
04/02/25 Tender

Director

31,561 0.0302%
04/02/25 Tender

General Counsel

180,044 0.1725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-.--%-.--%-65.07% 383M
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -0.66%-3.05%+23.46%+46.51% 369.76B
Weighted average by Cap. -0.60%-3.32%+29.07%+71.14%

Financials

2022 2023
Net sales 133M 118M 110M 100M 189M 12.74B 191M 1.33B 516M 6.51B 498M 487M 20.91B 234M 208M 194M 177M 334M 22.5B 337M 2.35B 910M 11.5B 879M 860M 36.91B
Net income -356M -317M -296M -269M -508M -34.26B -513M -3.58B -1.39B -17.52B -1.34B -1.31B -56.22B -324M -288M -269M -245M -462M -31.15B -466M -3.25B -1.26B -15.92B -1.22B -1.19B -51.1B
Net Debt 77.76M 69.09M 64.48M 58.78M 111M 7.48B 112M 780M 302M 3.82B 292M 286M 12.26B 225M 199M 186M 170M 320M 21.58B 323M 2.25B 873M 11.03B 843M 825M 35.41B
Logo Revance Therapeutics, Inc.
Revance Therapeutics Inc is a United States-based pharmaceutical preparation manufacturing company. The Company operates as a biotechnology company that develops, manufactures, and markets aesthetic and therapeutic products. It offers products and services, such as DAXXIFY (DaxibotulinumtoxinA-lanm) and resilient hyaluronic acid (RHA) collection, includes aesthetics and therapeutics.
Employees
597
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RVNC Stock